Cognitive burden and polypharmacy in elderly Japanese patients treated with anticholinergics for an overactive bladder.
anticholinergics
cognition
elderly
overactive bladder
polypharmacy
Journal
Lower urinary tract symptoms
ISSN: 1757-5672
Titre abrégé: Low Urin Tract Symptoms
Pays: Australia
ID NLM: 101506777
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
20
05
2019
revised:
09
07
2019
accepted:
26
07
2019
pubmed:
29
8
2019
medline:
15
12
2020
entrez:
29
8
2019
Statut:
ppublish
Résumé
This study aimed to investigate the cognitive burden and polypharmacy in elderly patients treated with anticholinergics for an overactive bladder. We conducted a retrospective study of patients with an overactive bladder receiving treatment at two hospitals in Japan (Nara Medical University Hospital and Saiseikai Nara Hospital). Prescription data were collected from the medical records of the patients registered between January 2013 and April 2014. The Anticholinergic Cognitive Burden Scale was used to estimate the severity of the anticholinergic effects on the cognition of each patient. We collected the prescription data of 584 and 246 patients from the Nara Medical University Hospital and Saiseikai Nara Hospital, respectively. The mean daily total Anticholinergic Cognitive Burden score ranged between 3 and 4 (3.59 ± 1.16 at Nara Medical University Hospital vs 3.32 ± 0.78 at Saiseikai Nara Hospital, P < 0.01). At both hospitals, the mean number of prescriptions was >5 in patients ≥75 years (5.95 ± 4.43 and 5.64 ± 3.90 at Nara Medical University Hospital and Saiseikai Nara Hospitals, respectively). Our findings suggest that 10%-20% of elderly patients (≥65 years) receiving treatment with anticholinergics for an overactive bladder are in a state of polypharmacy. The total anticholinergic cognitive burden of each patient mainly depends on the anticholinergics being used for treating the overactive bladder. Especially for elderly patients with a high risk of adverse effects, including cognitive impairment, careful attention needs to be paid during selection of drugs for treating patients with an overactive bladder.
Substances chimiques
Cholinergic Antagonists
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
54-61Informations de copyright
© 2019 John Wiley & Sons Australia, Ltd.
Références
Population Estimates by Age (Five-Year Groups) and Sex - October 1, 2017(Final estimates), March 1, 2018 (Provisional estimates). Available from: Portal site of official statistics of Japan https://www.e-stat.go.jp/en/stat-search/files?page=1&layout=dataset&toukei=00200524&bunya_l=02&tstat=000000090001&stat_infid=000031681832&result_page=1. Accessed May 1, 2019.
Funada S, Kawaguchi T, Terada N, et al. Cross-sectional epidemiological analysis of the Nagahama study for correlates of overactive bladder: genetic and environmental considerations. J Urol. 2018;199:774-778.
Homma Y, Yamaguchi O, Hayashi K. Neurogenic bladder society C. an epidemiological survey of overactive bladder symptoms in Japan. BJU Int. 2005;96:1314-1318.
Nambiar AK, Bosch R, Cruz F, et al. EAU guidelines on assessment and nonsurgical Management of Urinary Incontinence. Eur Urol. 2018;73:596-609.
Chapple CR, Kaplan SA, Mitcheson D, et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a beta(3)-adrenoceptor agonist, in overactive bladder. Eur Urol. 2013;63:296-305.
Maman K, Aballea S, Nazir J, et al. Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison. Eur Urol. 2014;65:755-765.
Benner JS, Nichol MB, Rovner ES, et al. Patient-reported reasons for discontinuing overactive bladder medication. BJU Int. 2010;105:1276-1282.
Lunevicius R, Haagsma JA. Incidence and mortality from adverse effects of medical treatment in the UK, 1990-2013: levels, trends, patterns and comparisons. Int J Qual Health Care. 2018;30:558-564.
Mizokami F, Koide Y, Noro T, Furuta K. Polypharmacy with common diseases in hospitalized elderly patients. Am J Geriatr Pharmacother. 2012;10:123-128.
Sarkar U, Lopez A, Maselli JH, Gonzales R. Adverse drug events in U.S. adult ambulatory medical care. Health Serv Res. 2011;46:1517-1533.
Thomsen LA, Winterstein AG, Sondergaard B, Haugbolle LS, Melander A. Systematic review of the incidence and characteristics of preventable adverse drug events in ambulatory care. Ann Pharmacother. 2007;41:1411-1426.
Ancelin ML, Artero S, Portet F, Dupuy AM, Touchon J, Ritchie K. Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. BMJ. 2006;332:455-459.
Scheife R, Takeda M. Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly. Clin Ther. 2005;27:144-153.
By the American Geriatrics Society Beers Criteria Update Expert P. American Geriatrics Society 2015 updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;63:2227-2246.
Yoshida M, Kato D, Nishimura T, Van Schyndle J, Uno S, Kimura T. Anticholinergic burden in the Japanese elderly population: use of antimuscarinic medications for overactive bladder patients. Int J Urol. 2018;25:855-862.
Cai X, Campbell N, Khan B, Callahan C, Boustani M. Long-term anticholinergic use and the aging brain. Alzheimers Dement. 2013;9:377-385.
Chancellor MB, Staskin DR, Kay GG, Sandage BW, Oefelein MG, Tsao JW. Blood-brain barrier permeation and efflux exclusion of anticholinergics used in the treatment of overactive bladder. Drugs Aging. 2012;29:259-273.
Yamagami H, Imura M, Hiro S. The demographics and treatment circumstances of patients receiving OAB treatment medication. Jpn J Urol Surg. 2014;27:1183-1190.
Suzuki Y, Akishita M, Arai H, Teramoto S, Morimoto S, Toba K. Multiple consultations and polypharmacy of patients attending geriatric outpatient units of university hospitals. Geriatr Gerontol Int. 2006;6:244-247.
Nomoto S, Nakanishi Y. Investigation of polypharmacy in late-stage elderly patients visiting a community hospital outpatient unit. Nihon Ronen Igakkai Zasshi. 2011;48:276-281.
Kojima T, Akishita M, Kameyama Y, et al. High risk of adverse drug reactions in elderly patients taking six or more drugs: analysis of inpatient database. Geriatr Gerontol Int. 2012;12:761-762.
Kojima T, Akishita M, Nakamura T, et al. Polypharmacy as a risk for fall occurrence in geriatric outpatients. Geriatr Gerontol Int. 2012;12:425-430.
Lai HH, Shen B, Rawal A, Vetter J. The relationship between depression and overactive bladder/urinary incontinence symptoms in the clinical OAB population. BMC Urol. 2016;16:60.
Torimoto K, Matsushita C, Yamada A, et al. Clinical efficacy and safety of mirabegron and imidafenacin in women with overactive bladder: a randomized crossover study (the MICRO study). NeurourolUrodyn. 2017;36:1097-1103.
Wagg A, Dale M, Tretter R, Stow B, Compion G. Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study. Eur Urol. 2013;64:74-81.
Sakakibara R, Hamano H, Yagi H. Cognitive safety and overall tolerability of Imidafenacin in clinical use: a long-term, open-label, post-marketing surveillance study. Low Urin Tract Symptoms. 2014;6:138-144.
Sakakibara R, Tateno F, Yano M, et al. Imidafenacin on bladder and cognitive function in neurologic OAB patients. Clin Auton Res. 2013;23:189-195.
Shiota T, Torimoto K, Momose H, et al. Temporary cognitive impairment related to administration of newly developed anticholinergic medicines for overactive bladder: two case reports. BMC Res Notes. 2014;7:672.
Boustani M, Campbell N, Munger S, Maidment I, Fox C. Impact of anticholinergics on the aging brain: a review and practical application. Aging Health. 2008;4:311-320.
Campbell NL, Lane KA, Gao S, Boustani MA, Unverzagt F. Anticholinergics influence transition from Normal cognition to mild cognitive impairment in older adults in primary care. Pharmacotherapy. 2018;38:511-519.
Campbell NL, Perkins AJ, Bradt P, et al. Association of Anticholinergic Burden with cognitive impairment and health care utilization among a diverse ambulatory older adult population. Pharmacotherapy. 2016;36:1123-1131.
Gray SL, Anderson ML, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175:401-407.
Yoshida M, Takeda M, Gotoh M, Nagai S, Kurose T. Vibegron, a novel potent and selective beta3-Adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study. Eur Urol. 2018;73:783-790.